The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Enasidenib-Global Market Insights and Sales Trends 2024
Synopsis
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
The global Enasidenib market size is expected to reach US$ 125.9 million by 2029, growing at a CAGR of 7.1% from 2023 to 2029. The market is mainly driven by the significant applications of Enasidenib in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Enasidenib market. 50mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 100mg segment is estimated at % CAGR for the next seven-year period.
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Enasidenib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Enasidenib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Enasidenib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Enasidenib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Enasidenib covered in this report include Bristol Myers Squibb. etc.
The global Enasidenib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol Myers Squibb
Global Enasidenib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Enasidenib market, Segment by Type:
50mg
100mg
Global Enasidenib market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Enasidenib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Enasidenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
The global Enasidenib market size is expected to reach US$ 125.9 million by 2029, growing at a CAGR of 7.1% from 2023 to 2029. The market is mainly driven by the significant applications of Enasidenib in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Enasidenib market. 50mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 100mg segment is estimated at % CAGR for the next seven-year period.
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Enasidenib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Enasidenib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Enasidenib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Enasidenib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Enasidenib covered in this report include Bristol Myers Squibb. etc.
The global Enasidenib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol Myers Squibb
Global Enasidenib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Enasidenib market, Segment by Type:
50mg
100mg
Global Enasidenib market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Enasidenib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Enasidenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Enasidenib Market Overview
1.1 Enasidenib Product Overview
1.2 Enasidenib Market Segment by Type
1.2.1 50mg
1.2.2 100mg
1.3 Global Enasidenib Market Size by Type
1.3.1 Global Enasidenib Market Size Overview by Type (2018-2029)
1.3.2 Global Enasidenib Historic Market Size Review by Type (2018-2023)
1.3.3 Global Enasidenib Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Enasidenib Sales Breakdown by Type (2018-2023)
1.4.2 Europe Enasidenib Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Enasidenib Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Enasidenib Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Enasidenib Sales Breakdown by Type (2018-2023)
2 Global Enasidenib Market Competition by Company
2.1 Global Top Players by Enasidenib Sales (2018-2023)
2.2 Global Top Players by Enasidenib Revenue (2018-2023)
2.3 Global Top Players by Enasidenib Price (2018-2023)
2.4 Global Top Manufacturers Enasidenib Manufacturing Base Distribution, Sales Area, Product Type
2.5 Enasidenib Market Competitive Situation and Trends
2.5.1 Enasidenib Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Enasidenib Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Enasidenib as of 2022)
2.7 Date of Key Manufacturers Enter into Enasidenib Market
2.8 Key Manufacturers Enasidenib Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Enasidenib Status and Outlook by Region
3.1 Global Enasidenib Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Enasidenib Historic Market Size by Region
3.2.1 Global Enasidenib Sales in Volume by Region (2018-2023)
3.2.2 Global Enasidenib Sales in Value by Region (2018-2023)
3.2.3 Global Enasidenib Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Enasidenib Forecasted Market Size by Region
3.3.1 Global Enasidenib Sales in Volume by Region (2024-2029)
3.3.2 Global Enasidenib Sales in Value by Region (2024-2029)
3.3.3 Global Enasidenib Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Enasidenib by Application
4.1 Enasidenib Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Enasidenib Market Size by Application
4.2.1 Global Enasidenib Market Size Overview by Application (2018-2029)
4.2.2 Global Enasidenib Historic Market Size Review by Application (2018-2023)
4.2.3 Global Enasidenib Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Enasidenib Sales Breakdown by Application (2018-2023)
4.3.2 Europe Enasidenib Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Enasidenib Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Enasidenib Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Enasidenib Sales Breakdown by Application (2018-2023)
5 North America Enasidenib by Country
5.1 North America Enasidenib Historic Market Size by Country
5.1.1 North America Enasidenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Enasidenib Sales in Volume by Country (2018-2023)
5.1.3 North America Enasidenib Sales in Value by Country (2018-2023)
5.2 North America Enasidenib Forecasted Market Size by Country
5.2.1 North America Enasidenib Sales in Volume by Country (2024-2029)
5.2.2 North America Enasidenib Sales in Value by Country (2024-2029)
6 Europe Enasidenib by Country
6.1 Europe Enasidenib Historic Market Size by Country
6.1.1 Europe Enasidenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Enasidenib Sales in Volume by Country (2018-2023)
6.1.3 Europe Enasidenib Sales in Value by Country (2018-2023)
6.2 Europe Enasidenib Forecasted Market Size by Country
6.2.1 Europe Enasidenib Sales in Volume by Country (2024-2029)
6.2.2 Europe Enasidenib Sales in Value by Country (2024-2029)
7 Asia-Pacific Enasidenib by Region
7.1 Asia-Pacific Enasidenib Historic Market Size by Region
7.1.1 Asia-Pacific Enasidenib Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Enasidenib Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Enasidenib Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Enasidenib Forecasted Market Size by Region
7.2.1 Asia-Pacific Enasidenib Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Enasidenib Sales in Value by Region (2024-2029)
8 Latin America Enasidenib by Country
8.1 Latin America Enasidenib Historic Market Size by Country
8.1.1 Latin America Enasidenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Enasidenib Sales in Volume by Country (2018-2023)
8.1.3 Latin America Enasidenib Sales in Value by Country (2018-2023)
8.2 Latin America Enasidenib Forecasted Market Size by Country
8.2.1 Latin America Enasidenib Sales in Volume by Country (2024-2029)
8.2.2 Latin America Enasidenib Sales in Value by Country (2024-2029)
9 Middle East and Africa Enasidenib by Country
9.1 Middle East and Africa Enasidenib Historic Market Size by Country
9.1.1 Middle East and Africa Enasidenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Enasidenib Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Enasidenib Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Enasidenib Forecasted Market Size by Country
9.2.1 Middle East and Africa Enasidenib Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Enasidenib Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bristol Myers Squibb
10.1.1 Bristol Myers Squibb Company Information
10.1.2 Bristol Myers Squibb Introduction and Business Overview
10.1.3 Bristol Myers Squibb Enasidenib Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bristol Myers Squibb Enasidenib Products Offered
10.1.5 Bristol Myers Squibb Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Enasidenib Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Enasidenib Industrial Chain Analysis
11.4 Enasidenib Market Dynamics
11.4.1 Enasidenib Industry Trends
11.4.2 Enasidenib Market Drivers
11.4.3 Enasidenib Market Challenges
11.4.4 Enasidenib Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Enasidenib Distributors
12.3 Enasidenib Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
